This editorial refers to 'The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials' † , by D. Preiss et al., on page 1536.
The Scandinavian Simvastatin Survival Study (4S) showed that patients with coronary heart disease without HF benefited from long-term simvastatin treatment by a 30% reduction in all-cause mortality during 5.4 years follow-up. 5 Retrospective analysis also demonstrated a 19% reduction in the report of new-onset HF. 6 Almost half the patients with new-onset HF had a non-fatal myocardial infarct prior to the registration of HF. Incident HF quadruples the risk for cardiovascular events, and this therefore has important clinical implications. Because of the higher risk, absolute treatment benefit will be larger. Studies that are more recent have added uncertainty to the alleged preventive effects of statin on incident HF. 7 -9 Some of the discrepancies are due to different definitions of HF, exclusion of early-onset HF after an acute MI because they are assumed to be one event, different statin dose regimens, and missing sensitive biomarkers of acute myocardial infarcts and left ventricular dysfunction. It is therefore commendable that Preiss and co-workers have examined the statin effects on the risk of HF hospitalization and HF death by analysing all primary and secondary randomized controlled trials with statins between 1994 and 2014 in a standardized fashion. Although Preiss et al. observed a clear reduction in LDL and nonfatal MI, these effects were not related to the risk of first non-fatal or fatal HF event. Less than 15% of the first HF endpoints were preceded by a documented myocardial infarct. The small number may have been underestimated due to the low incidence of MI, heterogeneity in the HF diagnosis, insensitive diagnostic biomarkers, and that the study excluded patients with incident HF within 30 days after a myocardial infarct. Furthermore, the analysis did not demonstrate any different effect of statins on HF outcomes related to an in-study MI or not. This may not be surprising since it takes between 6 and 12 months to observe treatment effects of statins. However, registry studies have observed that early statin therapy of acute MI was associated with a significantly lower rate of early complications including HF events as compared with no statin therapy. Results derived from registry studies are difficult to interpret because of allocation bias. The interpretation is also limited by the fact that patients were not randomized for occurrence or non-occurrence of MI.
The effect of statins on the composite endpoint of non-fatal HF hospitalizations and HF death was exclusively driven by incident nonfatal HF hospitalization with no effect on HF mortality. HF death is an end-stage that primarily follows extensive left ventricular
The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology. † doi:10.1093/eurheartj/ehv072. dysfunction. The cause and mode of death differ between patients with stable coronary artery disease without HF and patients with established HF. Non-HF patients are more likely to die suddenly from acute MI and ventricular fibrillation. In contrast, HF patients die primarily from progressive HF and stroke. 4, 12 It is therefore not surprising that statins have no effect on HF deaths. The same contrast between statin effects on non-fatal HF hospitalization and HF deaths was observed in the CORONA and GISSI trials, where patients with documented HF were treated with rosuvastatin. 13, 14 There was no effect of rosuvastatin treatment on HF death, but benefits for nonfatal HF hospitalization and atherosclerotic events were observed.
11
Acute coronary events and incidence of HF are declining due to effective preventive treatment of arteriosclerosis including statins, yet the prevalence of HF is increasing. 15 The improved survival among HF patients is caused by interventions that target downstream pathophysiological mechanisms by unloading the failing left ventricle and by blunting detrimental effects of neurohormonal activation (betablockers, renin -angiotensin -aldosterone inhibitors, and resynchronization devices), thereby reducing myocardial energy requirement and electrical instability. Conversely, beta-blockers and inhibitors of the renin-angiotensin -aldosterone system have small and insignificant effects in stable coronary disease without HF. 16 The target for statin treatment in patients with stable coronary artery disease is the development of coronary and cerebral arteriosclerosis, 1,2 but this has minor impact in patients with established HF 13 mostly because the events are determined by the failing myocardium and less by progression of atherosclerosis. However, a retrospective analysis of CORONA, restricted to 'atherothrombotic' events, defined as fatal and non-fatal MI and fatal and non-fatal non-ischaemic strokes, showed a borderline significant difference favouring rosuvastatin (P ¼ 0.05). Preiss et al. also suggest other explanations whereby statins may reduce the risk of developing HF by preventing ischaemic events including pleiotropic antiinflammatory effects unrelated to the LDL-lowering effect. This might be interesting especially because HF is a driver of inflammation, but the lack of statin effects in established HF on major composite endpoints 13, 14 and the recent positive results of the IMPROVE-IT with ezetimibe, a non-statin, cholesterol-lowering agent, probably brought this discussion to an end. 17 The study by Preiss and co-workers is important because incident HF carries a dismal prognosis. It reminds us that prevention of newonset HF can be achieved by statin treatment. This is different from prevention of HF death, which primarily is determined by mechanisms most probably dependent on left ventricular remodelling and myocardial dysfunction. The study therefore also suggests different aetiologies for non-fatal HF events and fatal HF. For the same reason, the two endpoints should not be lumped together in clinical studies. Prevention of new-onset HF and HF hospitalization requires a treatment approach that is different from treatment of established HF and prevention of HF death (Figure 1) .
Conflict of interest: none declared. Figure 1 Schematic flow diagram of evolving targets and treatment allocations in ischaemic heart disease. Different targets and treatment allocations are indicated for first non-fatal heart failure and established heart failure, according to the different mechanisms involved. ACI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CRT, cardiac resynchronization therapy; ICD, implantable cardioverter defibrillator; LV, left ventricular; MRA, mineralocorticoid receptor antagonist.
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